Soy phytoestrogens are naturally occurring compounds that contain isoflavones, which have estrogenic properties and can bind to estrogen receptors in bone tissue. As a result of these properties, isoflavones are being examined as alternatives to conventional hormone replacement therapy (HRT). The goal of this randomized placebo-controlled crossover trial was to investigate the effect of isoflavone supplementation (110 mg/d) on bone mass and markers of bone turnover in healthy postmenopausal women for 6 months. Nineteen women were recruited to participate in the study. Subjects were excluded if they had been on HRT in the previous 3 months, were within 8 years past menopause, had a history of bone, kidney, endocrine, or liver disease, or used medications that affect bone. Serum samples were assayed for osteocalcin and bone specific alkaline phosphatase (BSAP). Urine samples were assayed for type 1 collagen α1 chain helical peptide (HP). Lumbar spine and hip bone mineral content (BMC) and density (BMD) were measured via DEXA. The mean age of the study population was 70.6 ± 6.3 years, and the mean years since menopause was 19.1 ± 5.5 years. There was a significant difference in HP levels when treatment (43.43 ± 22.81 μg/mmol cr) was compared to control (56.29 ± 31.50 μg/mmol cr) (p 0.05), and HP concentrations decreased by 37% during the treatment phase to premenopausal levels. Serum osteocalcin decreased during the treatment phase compared to pre-treatment for both crossover groups (p 0.05), and serum BSAP levels were lower for the treatment (23.91 ± 7.13 U/L) compared to the control (24.94 ± 6.55 U/L) but not significantly lower. There was a 3.5% increase in lumbar spine BMC and 1% increase in lumbar spine BMD after treatment. Total hip BMC and BUD increased by 3.6% and 1.3%, respectively. These data suggest that isoflavone supplementation favorably altered postmenopausal bone turnover rates by significantly decreasing bone resorption, modestly decreasing the rate of bone formation, and thus the net effect is on increased bone mass.
展开▼
机译：大豆植物雌激素是含有异黄酮的天然化合物，具有异黄酮的特性，可以与骨组织中的雌激素受体结合。由于这些特性，正在研究异黄酮作为常规激素替代疗法（HRT）的替代方法。这项随机安慰剂对照交叉试验的目标是研究补充异黄酮（110毫克/天）对健康绝经后妇女6个月内骨质和骨转换指标的影响。招募了19名妇女参加该研究。如果受试者在过去3个月内接受过HRT治疗，更年期后8年内，有骨，肾，内分泌或肝病病史或使用过会影响骨骼的药物，则将其排除在外。测定血清样品中的骨钙素和骨特异性碱性磷酸酶（BSAP）。分析尿液样本中的1型胶原α1链螺旋肽（HP）。腰椎和髋骨矿物质含量（BMC）和密度（BMD）通过DEXA测量。研究人群的平均年龄为70.6±6.3岁，绝经后的平均年龄为19.1±5.5岁。当将治疗（43.43±22.81μg/ mmol cr）与对照组（56.29±31.50μg/ mmol cr）进行比较时，HP水平存在显着差异（p <0.05），并且HP浓度在治疗阶段降低了37％绝经前水平。与交叉治疗组相比，治疗前的血清骨钙素水平下降（p <0.05），与对照组相比，治疗组的血清BSAP水平较低（23.91±7.13 U / L）（24.94±6.55 U / L） ），但不会明显降低。治疗后，腰椎BMC增加3.5％，腰椎BMD增加1％。髋关节总BMC和BUD分别增加3.6％和1.3％。这些数据表明，异黄酮补充剂通过显着降低骨吸收，适度降低骨形成速率，从而有利地改变了绝经后的骨转换率，因此净效应是增加了骨量。
展开▼
